Flux Peptides
$0.00 0

Cart

No products in the cart.

Thymosin Alpha-1 10mg

$80.00

Thymosin alpha 1 (Ta1) is an N terminally acetylated 28 amino acid peptide first isolated from calf thymus tissue in 1977. Its international nonproprietary name is thymalfasin. It is sold as a prescription medicine under the brand name Zadaxin in some countries and is authorised in Italy, but the FDA has stated that Ta1 is not approved in the United States, Japan or Europe outside Italy, and Health Canada’s Drug Product Database lists no product containing it. The lyophilized material on this page is a research chemical and is not Zadaxin.

  • Purity: greater than or equal to 99.0 percent (HPLC tested)
  • Pathways studied: T cell differentiation markers and Toll like receptor 9 dependent signalling in dendritic cells
  • Format: Lyophilized powder for laboratory research
  • Key Research Focus: T cell differentiation markers and cytokine measurement in immunology models
  • Storage: Store at minus 20 degrees Celsius, sealed and protected from light and moisture
Category:

Description

Thymosin Alpha-1 Overview

Thymosin alpha 1 (Ta1) is a small acidic peptide that was isolated from calf thymus tissue and sequenced by Goldstein and colleagues in 1977, as one of the components of the preparation then called thymosin fraction 5. It is 28 amino acids long and is acetylated at the N terminus. The synthetic peptide carries the international nonproprietary name thymalfasin. Ta1 is used in immunology research as a reference peptide when measuring T cell differentiation markers and cytokine readouts.

No single high affinity receptor has been established for Ta1. Published mechanistic work has reported signalling that depends on Toll like receptor 9 in dendritic cells, and this remains an active research question rather than a settled pathway.

Regulatory status

Ta1 is marketed as a prescription medicine under the brand name Zadaxin (SciClone Pharmaceuticals). In a December 2024 review presented to its Pharmacy Compounding Advisory Committee, the FDA stated that Ta1 is not approved in the United States, Japan or Europe with the exception of Italy, and that it is not recognized in the European or Japanese Pharmacopoeias. The FDA also noted that claims of approval across the Asia Pacific region, Latin America, Eastern Europe and the Middle East could not be independently verified, and that it has approved no drug product containing Ta1. The European Medicines Agency granted thymalfasin an EU orphan designation for hepatocellular carcinoma on 30 July 2002; an orphan designation is not a marketing authorisation.

Health Canada’s Drug Product Database contains no drug product with thymalfasin or thymosin alpha 1 as an active ingredient, so it is not authorized for sale as a drug in Canada. The material offered on this page is a laboratory research chemical. It is not Zadaxin, it is not a licensed or authorized medicine in Canada, and it is not supplied for any medical purpose.

Technical Specifications

  • Peptide name: Thymosin alpha 1
  • Synonyms: Ta1, thymalfasin
  • CAS number: 62304-98-7 (free base)
  • Molecular formula: C129H215N33O55 (free base)
  • Molar mass: 3108.3 g/mol (free base)
  • Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
  • UNII: W0B22ISQ1C
  • Purity: greater than or equal to 99.0 percent (determined by HPLC)
  • Appearance: White to off white lyophilized powder
  • Solubility: Soluble in sterile water

Research Context

Reported areas of study, with the evidence level stated:

  • T cell differentiation markers: cell culture and animal work has examined Ta1 in relation to the differentiation of thymocyte precursors and to CD4 and CD8 positive T cell populations.
  • Cytokine readouts: in vitro studies have measured interleukin 2 and interferon gamma among other cytokines after exposure to Ta1.
  • Toll like receptor 9: dendritic cell studies have reported Ta1 signalling that depends on Toll like receptor 9 and have used it to examine antigen presentation.
  • Clinical evidence: Ta1 has been studied in human trials across a number of conditions. In its December 2024 review the FDA concluded that the available evidence was insufficient to support effectiveness for the uses it evaluated, and that the studies were inconclusive and limited by small sample sizes and design deficiencies. No clinical claim for this material is made or implied.

Storage and Handling

  • Lyophilized powder: store at minus 20 degrees Celsius (minus 4 degrees Fahrenheit) for up to 36 months, sealed and protected from light and moisture.
  • Reconstituted solution: store at 4 degrees Celsius (39 degrees Fahrenheit), protected from light, for up to 21 days, and avoid repeated freeze and thaw cycles.
  • Handling: standard laboratory safety practice applies. This product is for laboratory research use only.

Testing and Quality Control

Every batch of Thymosin Alpha-1 10mg undergoes:

  1. HPLC (high performance liquid chromatography): purity reported as greater than or equal to 99.0 percent.
  2. MS (mass spectrometry): confirms the molecular mass expected for the acetylated 28 residue sequence.
  3. Appearance and identity checks on the lyophilized cake.

HPLC and mass spectrometry characterize chemical purity and identity. They do not measure biological activity, and no potency testing is performed or implied.

For laboratory research use only. Not for human or veterinary use.

Further reading